Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroblastoma | 29 | 2023 | 1226 | 3.130 |
Why?
|
3-Iodobenzylguanidine | 7 | 2023 | 115 | 0.850 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2022 | 903 | 0.780 |
Why?
|
Interleukin-2 | 3 | 2019 | 1904 | 0.710 |
Why?
|
Isotretinoin | 1 | 2019 | 114 | 0.650 |
Why?
|
Facial Paralysis | 2 | 2021 | 338 | 0.500 |
Why?
|
Sesquiterpenes | 4 | 2003 | 177 | 0.420 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 9239 | 0.420 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2016 | 740 | 0.380 |
Why?
|
Aminopeptidases | 3 | 2005 | 88 | 0.380 |
Why?
|
Antibodies, Monoclonal | 3 | 2019 | 9274 | 0.350 |
Why?
|
Metalloendopeptidases | 3 | 2005 | 396 | 0.340 |
Why?
|
Chlorobenzenes | 2 | 2005 | 28 | 0.320 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 11524 | 0.300 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1363 | 0.240 |
Why?
|
Radiotherapy | 1 | 2011 | 1533 | 0.240 |
Why?
|
Chromosomes, Human, Pair 16 | 2 | 2002 | 354 | 0.240 |
Why?
|
Child, Preschool | 22 | 2023 | 41006 | 0.220 |
Why?
|
Antineoplastic Agents | 9 | 2019 | 13695 | 0.220 |
Why?
|
Child | 29 | 2023 | 77709 | 0.210 |
Why?
|
Angiogenesis Inhibitors | 3 | 2001 | 2038 | 0.210 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2005 | 3557 | 0.210 |
Why?
|
Neoplasms | 7 | 2023 | 21683 | 0.210 |
Why?
|
Salvage Therapy | 2 | 2021 | 1275 | 0.200 |
Why?
|
Whole-Body Irradiation | 2 | 2016 | 449 | 0.180 |
Why?
|
Lymphoproliferative Disorders | 1 | 2021 | 523 | 0.150 |
Why?
|
Neovascularization, Pathologic | 2 | 2005 | 2635 | 0.150 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2017 | 136 | 0.150 |
Why?
|
Palliative Care | 2 | 2023 | 3493 | 0.140 |
Why?
|
Attitude to Death | 1 | 2019 | 382 | 0.140 |
Why?
|
Gene Fusion | 1 | 2019 | 371 | 0.140 |
Why?
|
Septum Pellucidum | 1 | 1996 | 58 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5172 | 0.140 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 332 | 0.130 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.130 |
Why?
|
Pyrroles | 2 | 2011 | 1146 | 0.130 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4933 | 0.120 |
Why?
|
Carbazoles | 2 | 2019 | 226 | 0.120 |
Why?
|
Bone Neoplasms | 2 | 2017 | 2529 | 0.120 |
Why?
|
Hypopituitarism | 1 | 1996 | 254 | 0.120 |
Why?
|
Maximum Tolerated Dose | 5 | 2021 | 892 | 0.120 |
Why?
|
Cyclohexanes | 4 | 2003 | 152 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2022 | 5442 | 0.120 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5221 | 0.120 |
Why?
|
Feasibility Studies | 3 | 2019 | 5078 | 0.120 |
Why?
|
Azacitidine | 1 | 2015 | 347 | 0.110 |
Why?
|
Tubulin Modulators | 1 | 2013 | 110 | 0.110 |
Why?
|
Combined Modality Therapy | 6 | 2016 | 8642 | 0.110 |
Why?
|
Adolescent | 17 | 2023 | 85781 | 0.110 |
Why?
|
Indoles | 2 | 2011 | 1839 | 0.110 |
Why?
|
Optic Nerve | 1 | 1996 | 554 | 0.110 |
Why?
|
Radionuclide Imaging | 1 | 2017 | 2031 | 0.110 |
Why?
|
Adenoma | 1 | 2023 | 2174 | 0.110 |
Why?
|
Tympanic Membrane | 1 | 2014 | 225 | 0.110 |
Why?
|
Leukemia | 1 | 2000 | 1511 | 0.100 |
Why?
|
Lymphocyte Count | 2 | 2012 | 793 | 0.100 |
Why?
|
Facial Nerve | 1 | 2014 | 271 | 0.100 |
Why?
|
Mice, Nude | 3 | 2005 | 3689 | 0.100 |
Why?
|
Infant | 11 | 2023 | 35136 | 0.100 |
Why?
|
Tumor Cells, Cultured | 4 | 2005 | 6314 | 0.100 |
Why?
|
Humans | 44 | 2023 | 744343 | 0.100 |
Why?
|
Camptothecin | 1 | 2014 | 576 | 0.100 |
Why?
|
Receptors, KIR | 1 | 2010 | 113 | 0.090 |
Why?
|
Receptor, trkB | 1 | 2011 | 125 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2017 | 2645 | 0.090 |
Why?
|
Adoptive Transfer | 1 | 2012 | 844 | 0.090 |
Why?
|
Parents | 2 | 2023 | 3407 | 0.090 |
Why?
|
Survivors | 1 | 2000 | 2291 | 0.090 |
Why?
|
Recombinant Proteins | 1 | 2019 | 6622 | 0.090 |
Why?
|
Mice, SCID | 3 | 2005 | 2716 | 0.090 |
Why?
|
Treatment Outcome | 11 | 2022 | 63114 | 0.080 |
Why?
|
Communication | 2 | 2020 | 3749 | 0.080 |
Why?
|
Receptors, Interleukin-2 | 1 | 2010 | 573 | 0.080 |
Why?
|
Vincristine | 2 | 2021 | 1039 | 0.080 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1182 | 0.080 |
Why?
|
Transplantation, Autologous | 3 | 2022 | 2124 | 0.080 |
Why?
|
Prospective Studies | 6 | 2023 | 53288 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13102 | 0.080 |
Why?
|
Education | 1 | 2011 | 543 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2015 | 1023 | 0.080 |
Why?
|
Receptors, IgG | 1 | 2010 | 582 | 0.070 |
Why?
|
Young Adult | 9 | 2023 | 56430 | 0.070 |
Why?
|
Cyclophosphamide | 2 | 2005 | 2242 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 973 | 0.070 |
Why?
|
Loss of Heterozygosity | 3 | 2006 | 684 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2015 | 10180 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 2282 | 0.070 |
Why?
|
Oncogene Proteins | 3 | 2005 | 749 | 0.070 |
Why?
|
Adult | 9 | 2023 | 214055 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 5 | 2023 | 5535 | 0.070 |
Why?
|
Male | 17 | 2021 | 350118 | 0.060 |
Why?
|
Sulfonamides | 1 | 2013 | 1938 | 0.060 |
Why?
|
Dendritic Cells | 1 | 2015 | 2725 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5686 | 0.060 |
Why?
|
Nurses | 1 | 2013 | 2461 | 0.060 |
Why?
|
Thiazoles | 1 | 2011 | 1483 | 0.060 |
Why?
|
Prognosis | 5 | 2022 | 29063 | 0.050 |
Why?
|
Bone Marrow Transplantation | 2 | 2001 | 2765 | 0.050 |
Why?
|
Mice, Inbred Strains | 1 | 2005 | 1827 | 0.050 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2003 | 437 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2015 | 10481 | 0.050 |
Why?
|
Genes, myc | 1 | 2003 | 399 | 0.050 |
Why?
|
Female | 17 | 2023 | 380194 | 0.050 |
Why?
|
Caregivers | 1 | 2013 | 2094 | 0.050 |
Why?
|
Lactams, Macrocyclic | 1 | 2023 | 320 | 0.050 |
Why?
|
Indazoles | 1 | 2022 | 289 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 627 | 0.050 |
Why?
|
Chromosome Aberrations | 2 | 2006 | 1813 | 0.050 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 26 | 0.050 |
Why?
|
Osteoradionecrosis | 1 | 2000 | 49 | 0.050 |
Why?
|
Genetic Linkage | 2 | 2002 | 2421 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2003 | 791 | 0.040 |
Why?
|
Aminopyridines | 1 | 2023 | 542 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2012 | 4665 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1832 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 2886 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2013 | 4234 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12959 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2022 | 2455 | 0.040 |
Why?
|
Pyrimidines | 1 | 2011 | 2942 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 2019 | 112 | 0.040 |
Why?
|
Goals | 1 | 2023 | 706 | 0.040 |
Why?
|
Calcitonin | 1 | 2019 | 336 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6895 | 0.040 |
Why?
|
Neovascularization, Physiologic | 2 | 2003 | 1351 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2000 | 401 | 0.040 |
Why?
|
Cell Division | 2 | 2003 | 4568 | 0.040 |
Why?
|
Benzamides | 1 | 2022 | 1379 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2000 | 692 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39050 | 0.030 |
Why?
|
Survival Analysis | 2 | 2009 | 10252 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1041 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2000 | 1401 | 0.030 |
Why?
|
Bone Marrow | 2 | 2009 | 2948 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2014 | 10943 | 0.030 |
Why?
|
Melanoma-Specific Antigens | 1 | 2015 | 80 | 0.030 |
Why?
|
Nuclear Proteins | 3 | 2005 | 5853 | 0.030 |
Why?
|
Growth Disorders | 1 | 2000 | 645 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2006 | 8428 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2000 | 683 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2005 | 9734 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1660 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 602 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2005 | 6489 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3508 | 0.030 |
Why?
|
Stem Cell Transplantation | 2 | 2016 | 1620 | 0.030 |
Why?
|
Suspensions | 1 | 2013 | 65 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2003 | 6171 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1364 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 2017 | 1032 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 196 | 0.030 |
Why?
|
Genome, Human | 2 | 2006 | 4420 | 0.030 |
Why?
|
Mice | 5 | 2005 | 81183 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2000 | 1598 | 0.030 |
Why?
|
Infertility | 1 | 2000 | 655 | 0.030 |
Why?
|
Cholestasis | 1 | 1996 | 378 | 0.030 |
Why?
|
Radiation Injuries | 1 | 2000 | 1180 | 0.030 |
Why?
|
Recurrence | 2 | 2015 | 8340 | 0.030 |
Why?
|
Quality of Life | 3 | 2019 | 12804 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2000 | 1061 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2000 | 4740 | 0.030 |
Why?
|
Blindness | 1 | 1996 | 617 | 0.030 |
Why?
|
Powders | 1 | 2011 | 80 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2022 | 77449 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2003 | 3023 | 0.030 |
Why?
|
Piperidines | 1 | 2019 | 1602 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20129 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2016 | 1462 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
Philadelphia | 1 | 2011 | 266 | 0.020 |
Why?
|
Syndrome | 1 | 1996 | 3251 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4554 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2002 | 17446 | 0.020 |
Why?
|
Furans | 1 | 2011 | 194 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2013 | 498 | 0.020 |
Why?
|
Motivation | 1 | 2019 | 1971 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2010 | 353 | 0.020 |
Why?
|
Hypoglycemia | 1 | 1996 | 861 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4851 | 0.020 |
Why?
|
Safety | 1 | 2013 | 1186 | 0.020 |
Why?
|
Animals | 5 | 2005 | 168757 | 0.020 |
Why?
|
Cardiomyopathies | 1 | 2000 | 1912 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
Emotions | 1 | 2019 | 2661 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 13989 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2015 | 1988 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 4751 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12788 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 35421 | 0.020 |
Why?
|
Antigens, Bacterial | 1 | 2012 | 1171 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2013 | 2879 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3229 | 0.020 |
Why?
|
Neutropenia | 1 | 2011 | 895 | 0.020 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 689 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
Cognition Disorders | 1 | 2000 | 4043 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2012 | 1348 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 9648 | 0.020 |
Why?
|
Decision Making | 1 | 2019 | 3887 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40075 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2013 | 1170 | 0.020 |
Why?
|
Influenza Vaccines | 1 | 2012 | 738 | 0.020 |
Why?
|
HLA Antigens | 1 | 2010 | 1381 | 0.020 |
Why?
|
Apoptosis | 1 | 2001 | 9727 | 0.020 |
Why?
|
Risk | 1 | 2016 | 9687 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2274 | 0.010 |
Why?
|
Immunotherapy, Adoptive | 1 | 2012 | 1270 | 0.010 |
Why?
|
Contrast Media | 1 | 2017 | 5300 | 0.010 |
Why?
|
Sarcoma | 1 | 2015 | 1897 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7913 | 0.010 |
Why?
|
Inhibitor of Differentiation Protein 2 | 1 | 2003 | 32 | 0.010 |
Why?
|
Ligands | 1 | 2010 | 3282 | 0.010 |
Why?
|
Transcription Factors | 1 | 2003 | 12208 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2013 | 1622 | 0.010 |
Why?
|
Administration, Oral | 1 | 2011 | 3913 | 0.010 |
Why?
|
Gene Targeting | 1 | 2006 | 880 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2015 | 3703 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2015 | 5097 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2017 | 11031 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5952 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1519 | 0.010 |
Why?
|
Hospitals, Pediatric | 1 | 2011 | 1775 | 0.010 |
Why?
|
Fibrosarcoma | 1 | 2003 | 348 | 0.010 |
Why?
|
Gene Dosage | 1 | 2006 | 1252 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2010 | 2133 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 2001 | 356 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4328 | 0.010 |
Why?
|
Phosphorylation | 1 | 2011 | 8436 | 0.010 |
Why?
|
Hospitals | 1 | 2013 | 3952 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2006 | 13033 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8324 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 19229 | 0.010 |
Why?
|
Random Allocation | 1 | 2003 | 2429 | 0.010 |
Why?
|
Patient Selection | 1 | 2011 | 4215 | 0.010 |
Why?
|
Gene Amplification | 1 | 2003 | 1063 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2015 | 7880 | 0.010 |
Why?
|
Drug Design | 1 | 2003 | 1076 | 0.010 |
Why?
|
Heart | 1 | 2011 | 4467 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 2649 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13284 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 25043 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12951 | 0.010 |
Why?
|
Pediatrics | 1 | 2011 | 3475 | 0.010 |
Why?
|
Cornea | 1 | 2003 | 1524 | 0.010 |
Why?
|
Cell Cycle | 1 | 2003 | 2967 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29786 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 40561 | 0.010 |
Why?
|
Models, Molecular | 1 | 2003 | 5456 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2003 | 2948 | 0.010 |
Why?
|
Pedigree | 1 | 2000 | 4644 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4456 | 0.010 |
Why?
|
Genomics | 1 | 2006 | 5720 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 9438 | 0.010 |
Why?
|
Mortality | 1 | 2001 | 2864 | 0.010 |
Why?
|
Risk Assessment | 1 | 2011 | 23338 | 0.010 |
Why?
|
Middle Aged | 1 | 2002 | 213383 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2003 | 14722 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2003 | 16689 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2001 | 19905 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2001 | 18029 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2003 | 20822 | 0.000 |
Why?
|